The failed Phase 3 trial severely damages fasedienol's probability of approval and the company's pipeline value. The post-hoc subgroup signal is unlikely to salvage the program without a costly new trial. With a $10M market cap and cash runway into 2027, the stock may see significant downside as the lead asset's path to market is now highly uncertain. Monitor for FDA meeting outcomes and potential financing needs.
Drug in focus
VTGN drug pipeline →fasedienol
▼ Bearish Named in this 8-K- Impact
- Phase
- Phase 3 (completed — two of three Phase 3 trials failed)
- Time to market
- Unknown — at least 3-5+ years if a new Phase 3 trial is required, with no guarantee of FDA acceptance of the proposed path
- Next catalyst
- None dated
What to watchFasedienol has now failed two consecutive Phase 3 trials (PALISADE-3 Dec 2025, PALISADE-4 June 2026). The stock traded at ~$2.04 before the PALISADE-4 miss and collapsed to ~$0.25, a ~$10M market cap. The company plans an FDA meeting for a potential new trial path, but the path to approval looks extremely long and uncertain. Watch for dilution risk as the company may need financing to fund any future trial.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 30 $0.2260entry
- T+1 · 5mo ago +7.52%α +7.66% · $0.2430
- T+5 · 4mo ago +8.76%α +8.16% · $0.2458
- T+20 · 4mo ago +1.86%α +2.89% · $0.2302
- T+60 · 8w ago +63.01%α +59.45% · $0.3684
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vistagen announced that its PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder failed to meet the primary endpoint (p=0.427) and secondary endpoints in the overall population. A post-hoc analysis showed nominal statistical significance in a subgroup of patients with very severe social anxiety (p=0.036), but this is exploratory and not confirmatory. The company plans to meet with the FDA to discuss a potential registrational pathway involving a single future Phase 3 trial, but the lead program's path to approval is now highly uncertain, representing a material negative catalyst for this $10M market cap biotech.
Key Facts
- PALISADE-4 Phase 3 trial of fasedienol failed to meet the primary endpoint (p=0.427) and secondary endpoints in the overall population (n=238).
- Fasedienol LS mean SUDS change was -9.5 vs placebo -11.4, difference 1.9 (p=0.427), not statistically significant.
- A post-hoc analysis in a subgroup with very severe SAD (n=123) showed nominal statistical significance (p=0.036), but this is exploratory and not confirmatory.
- Company plans to meet with FDA to discuss a potential registrational pathway involving a single future multi-dose Phase 3 trial with LSAS as primary endpoint, using prior PALISADE-2 data as confirmatory evidence.
- Company expects cash resources to support operations into 2027.
- Market cap is approximately $10M with 0% analyst bullish rating (7 Hold, 1 Sell, 2 Strong Sell).
Financial Impact
Lead pipeline asset fasedienol failed Phase 3 primary endpoint, severely diminishing probability of regulatory approval and commercial value. The company's $10M market cap reflects the high risk, but this failure materially reduces the already-low probability of success for the only late-stage asset.
Risk Factors
- FDA may not accept a registrational pathway based on a single future Phase 3 trial with confirmatory evidence from prior trials, given the PALISADE-4 failure.
- Post-hoc subgroup analysis is not confirmatory and may not be accepted by regulators as evidence of efficacy.
- Company may need additional financing to fund a new Phase 3 trial, potentially causing dilution at depressed share prices.
- Pipeline is entirely early-stage (Phase 2) with no other late-stage assets to offset fasedienol's setback.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-046143 |
| Document: vtgnex99120260630.htm | 0001628280-26-046143 |
| Document: vtgnex99220260630.htm | 0001628280-26-046143 |
| Document: 0001628280-26-046143-index-headers.html | 0001628280-26-046143 |
| Document: 0001628280-26-046143-index.html | 0001628280-26-046143 |
| Document: 0001628280-26-046143.txt | 0001628280-26-046143 |
Track record
21 reports on VTGN
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
- Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
- Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers